Can I Still Get the Flu Even If Vaccinated?

Flu vaccination cuts your risk of getting sick but does not eliminate it. Even in a good year, when the vaccine strains closely match what is circulating, overall effectiveness tends to land somewhere around 40 to 60 percent. In a bad year, it can be much lower. So yes, vaccinated people catch the flu regularly, and understanding why that happens reveals a lot about how influenza works and why the shot is still worth getting.

Why the Vaccine Does Not Stop Every Infection

Influenza viruses mutate constantly. The proteins on their surface shift just enough from one season to the next that last year’s immune memory, whether from a prior infection or a prior vaccine, does not always recognize this year’s virus. Vaccine manufacturers try to predict which strains will dominate months before flu season arrives, and sometimes they guess wrong. A systematic review and meta-analysis of test-negative studies found that protection was consistently highest against A(H1N1), moderate against influenza B, and lowest against A(H3N2), with effectiveness rising when the vaccine was a good antigenic match and dropping when it was not.¹ A decade-long study in South Korea put hard numbers on the gap: effectiveness averaged about 29 percent in seasons when vaccine and circulating strains matched, and actually dipped below zero in mismatched seasons, meaning vaccinated people in those years fared no better (and possibly slightly worse) than unvaccinated people statistically.²

The broad takeaway from this research is that the flu vaccine is not like the measles vaccine, which blocks infection in the vast majority of people for years. Flu vaccination is more like putting on a reasonably good raincoat: it will keep you dry in moderate rain, but a downpour can still soak you through. The virus’s constant shape-shifting is the fundamental reason, and it is why the vaccine has to be reformulated every year.³

The Egg Problem

Even when manufacturers pick the right strain, the manufacturing process can undermine the match. Most flu vaccines are still grown in chicken eggs, and the virus sometimes picks up mutations while adapting to that environment. Those egg-adapted changes can alter the very surface features the immune system needs to learn to recognize. During the 2012–2013 season, for instance, researchers found that the circulating H3N2 viruses were actually a good match to the recommended vaccine strain, but the egg-adapted version used in production had acquired three mutations near its binding site. Antibodies raised against the egg-grown virus showed a 16-fold drop in ability to recognize the real-world strain. The vaccine “mismatch” that year was not evolution in the wild virus but an artifact of how the vaccine was made.⁴

A similar story played out during the 2016–2017 season. The circulating H3N2 viruses had gained a sugar molecule (a glycosylation site) on one of their key surface proteins. When the vaccine strain was grown in eggs, it lost that sugar molecule, meaning the antibodies people developed after vaccination were poorly equipped to neutralize the glycosylated viruses they actually encountered.⁵ Cell-based and recombinant vaccines were developed partly to avoid this egg-adaptation problem, though head-to-head comparisons during the 2022–2023 season found cell-based and egg-based vaccines offered roughly comparable protection against hospitalization in adults under 65.⁶ Whether cell-based technology consistently delivers better real-world results remains an active area of research.

Your Age and Immune Status Change the Odds

Even a perfectly matched vaccine works differently in different bodies. As you age, your immune system becomes less responsive. Older adults produce fewer and lower-quality antibodies after vaccination, making them more vulnerable to breakthrough infections despite being among those who need the protection most.⁷ Specific defects pile up: the antibodies generated tend to bind the virus less tightly, and the immune cells responsible for switching to more powerful antibody types become sluggish.⁸

People with weakened immune systems from conditions like organ transplants, HIV, cancer treatment, or autoimmune therapies face a similar disadvantage. Vaccine responses tend to be blunted, and lower respiratory disease from influenza remains common in these groups even after vaccination.⁹ Obesity also appears to impair the immune response to flu vaccination, though the mechanisms are still being worked out.¹⁰

For adults 65 and older, high-dose flu vaccines were developed to compensate for the weaker immune response. A large trial found that the high-dose version reduced lab-confirmed flu by about 24 percent more than the standard dose in this age group.¹¹ A more recent trial with over 1.5 million participants confirmed the high-dose vaccine cut influenza-related hospitalizations by about 44 percent compared to standard-dose, though the broader benefit against all-cause hospitalization was smaller and not statistically clear-cut.¹² A systematic review spanning 12 influenza seasons and over 45 million older adults confirmed that the high-dose version consistently outperformed standard-dose across different age bands (65+, 75+, 85+) and regardless of which strain was circulating.¹³ The high-dose vaccine does not make older adults as protected as younger adults with a standard dose, but it meaningfully narrows the gap.

Breakthrough Infections Are Usually Milder

Here is where the conversation about flu vaccination often goes wrong. People frame effectiveness purely in terms of whether you get sick at all, but that misses a crucial dimension: vaccination consistently makes breakthrough infections less dangerous. Among hospitalized older adults who had been vaccinated, the odds of dying in the hospital dropped by about 64 percent compared to unvaccinated patients in one study.¹⁴

A narrative review pooling data from multiple studies found that vaccinated adults who were hospitalized with flu had roughly 26 percent lower odds of ending up in intensive care and about 31 percent lower odds of dying. Among children with breakthrough infections, vaccination was associated with a 45 percent reduction in the odds of developing fever, suggesting the immune system was mounting at least a partial defense even when it could not prevent infection entirely.¹⁵ Think of it this way: the vaccine may not stop the virus at the door, but it gives your immune system a head start that keeps the infection from spiraling into something severe.

Protection Against Heart Attacks and Strokes

One of the less intuitive benefits of flu vaccination has nothing to do with respiratory symptoms. Influenza infection triggers inflammation that can destabilize arterial plaques, raising the risk of heart attacks and strokes. A meta-analysis of clinical trials found that vaccinated individuals had about 30 percent fewer major cardiovascular events, including a meaningful reduction in heart-attack risk and cardiovascular death.¹⁶ An earlier observational study found vaccination was associated with a 19 percent reduction in hospitalizations for cardiac disease and a 16 to 23 percent reduction for stroke across two flu seasons in elderly populations.¹⁷ For anyone with existing heart disease, these benefits are arguably as important as avoiding a week of fever and body aches.

Timing Matters More Than Most People Realize

Vaccine-induced protection fades over the course of flu season. Antibody levels typically peak about a month after vaccination and decline from there.¹⁸ The practical consequence is that if you get vaccinated in early September and flu does not peak until February, your protection has already eroded substantially by the time you need it most. A meta-analysis found that effectiveness against A(H3N2) dropped by roughly 33 percentage points between the first three months after vaccination and the three months after that, while protection against influenza B dropped by about 19 points over the same window.¹⁹

This creates a genuine timing dilemma. Getting vaccinated too early means waning protection during peak flu activity. Getting vaccinated too late means you might catch the flu before your body has had time to mount a response, or you might simply forget to go. Modeling studies suggest that for older adults, delaying vaccination by a few weeks can prevent more cases in a late-peaking season, but the gains from strategic delay evaporate if the delay causes people to skip the vaccine altogether.²⁰ The pragmatic advice most health agencies settle on is to aim for September or October in the Northern Hemisphere, which puts peak protection roughly in line with the typical December-through-February flu season, while accepting that some late-season waning is the price of actually getting vaccinated.²¹

Does Getting Vaccinated Every Year Make It Less Effective?

This question has circled for years, and the evidence is legitimately complicated. A large meta-analysis of 41 studies found that people vaccinated in both the current and previous seasons showed modestly lower effectiveness compared to people vaccinated only in the current season: about 9 percentage points lower for A(H1N1), 18 points lower for A(H3N2), and 7 points lower for influenza B.²² A study in healthcare workers found a related pattern: after repeated vaccinations against the same strain, the antibody boost from each subsequent shot shrank, with the lowest fold-rise coming after the fourth and fifth doses of the same component.²³

That sounds alarming in isolation, but the same meta-analysis made an important distinction: in nearly every season, people vaccinated in both the current and previous years were still better protected than people who skipped the current year’s shot entirely. The small attenuation from repeat vaccination is real, but it does not come close to wiping out the benefit. Skipping a year “to reset” your immune system is not supported by the data and would leave you unprotected during the gap year. A concept called “original antigenic sin” is part of the explanation for why repeat exposure sometimes narrows the immune response. Your immune system tends to recall antibodies shaped by whatever flu strain it encountered first, even when a newer strain is the more relevant target.²⁴ Researchers have found that this imprinting is especially strong for antibodies targeting the stalk region of the virus’s surface protein, and that these stalk antibodies sometimes bind poorly to the strain that actually triggered the boost.²⁵ It is a fascinating immunological quirk, but the practical advice remains straightforward: get vaccinated every year.

Not Every “Flu” Is Actually Flu

A surprisingly large share of people who believe the flu vaccine “didn’t work” were never infected with influenza in the first place. Studies of people showing up with flu-like symptoms find that fewer than 25 percent actually test positive for influenza by PCR. Most have another respiratory virus, and in about half of all cases no pathogen is identified at all.²⁶ Rhinoviruses, coronaviruses (the common-cold kind), RSV, and parainfluenza viruses can all produce fever, body aches, and cough that feel identical to the flu. The flu vaccine offers zero protection against any of them.

One small randomized trial even found that children who received the inactivated flu vaccine had a higher rate of non-influenza respiratory infections compared to the placebo group, possibly because blocking one virus temporarily shifted the competitive landscape among respiratory pathogens.²⁷ That finding has not been consistently replicated and should be taken with caution, but it underscores an important point: the flu vaccine targets influenza specifically. If you get sick with something else two weeks after your flu shot, the vaccine is not to blame. The timing just makes it easy to draw the wrong conclusion.

Can a Vaccinated Person Still Spread the Flu?

Yes, though probably less efficiently. A household transmission study estimated that vaccination reduced the chance of passing the flu to household contacts by about 21 percent overall, though results varied dramatically by virus type: virtually no reduction for influenza A, but about 56 percent for influenza B.²⁸ This means vaccinated people who do get infected can still shed the virus and infect others, particularly when influenza A is the dominant circulating strain. A study of adults who received the live attenuated (nasal spray) vaccine found viral shedding in about 87 percent of participants on the first day, declining to 9 percent by day seven, with influenza B shedding lasting longer and at higher levels than influenza A.²⁹ For people living with elderly or immunocompromised family members, this is worth knowing: your vaccination helps, but it does not guarantee you will not bring the virus home.

The Search for a Universal Flu Vaccine

The reason we keep having this conversation year after year is that current flu vaccines chase a moving target. Researchers have been working on a universal influenza vaccine that would protect against many or all strains for multiple years, eliminating the annual guessing game. One promising approach targets the stalk region of the virus’s surface protein rather than the rapidly mutating head. The stalk is more conserved across different flu strains because it performs a critical structural function the virus cannot easily change. In animal studies, sequential vaccination with chimeric proteins that share the same stalk but carry different heads has successfully trained the immune system to focus antibodies on the stalk domain.³⁰ Several candidates are now in clinical trials. If one works, the concept of “flu vaccine effectiveness” would look very different, because the vaccine would no longer need to match the season’s dominant strain. That is still likely years away from routine use, but it represents a genuine shift in the field rather than incremental improvement.